Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
TruScreen Group Ltd. ( (NZ:TRU) ) has shared an update.
TruScreen Group has secured a trading halt on its shares on both the NZX and ASX, effective from the pre-market open on 21 May 2026, as it prepares a significant capital raising. Trading is expected to resume by 25 May 2026 or once the company announces completion of the placement.
The capital raising plan comprises a placement of up to NZ$1 million to institutional and selected investors and a one-for-five pro-rata renounceable rights issue targeting about NZ$1.94 million. TruScreen also intends to extend the expiry date of more than 204 million existing unlisted options to July 2027, a move that could strengthen its balance sheet flexibility and support ongoing growth in its global cervical screening business.
More about TruScreen Group Ltd.
TruScreen Group Ltd is a medical device company focused on cervical cancer screening, manufacturing an AI-enabled device that detects cervical tissue abnormalities in real time via optical and electrical measurements. Its TruScreen Ultra device is approved or registered in multiple markets including Australia, the U.K., China, Russia, Mexico, Vietnam and others, with over 200 devices installed globally and more than 200,000 examinations performed in the 2024 financial year.
Average Trading Volume: 309,998
Technical Sentiment Signal: Sell
Current Market Cap: N$13.45M
See more insights into TRU stock on TipRanks’ Stock Analysis page.